CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
临床前研究中腹腔给药靶向癌胚抗原的 CAR-T 细胞是有效治疗结直肠癌腹膜癌病的稳健递送途径
英文原题：Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
查看英文原题
Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
综合来看，我们的数据提示，i.p.
中文摘要
方法
构建第二代癌胚抗原（CEA）特异性CAR-T 细胞。在多种伴有腹腔内及腹腔外转移的PC动物模型中，分别经腹腔内或静脉（i.v.）给予CEA CAR-T 细胞。
结果
在PC动物模型中，与全身静脉输注相比，腹腔内给药的CAR-T 细胞抗肿瘤活性更强。此外，腹腔内给药可产生持久效应并预防肿瘤复发，在伴腹腔内或腹腔外器官转移的PC模型中也表现出强效抗肿瘤活性。与全身给药相比，对于无腹膜癌但存在腹腔外肿瘤的动物，腹腔内转移CAR-T 细胞也带来更强的抗肿瘤活性。随后在胰腺癌动物模型中，腹腔内给予新构建的靶向前列腺干细胞抗原CAR-T 细胞，进一步证实了这一现象。
结论
综上，研究数据提示，腹腔内给予CAR-T 细胞可能是有效治疗癌症的一种可靠递送途径。
展开英文摘要原文
METHODS
We generated second-generation carcinoembryonic antigen (CEA)-specific CAR T cells. Various animal models of PC with i.p. and extraperitoneal metastasis were treated by i.p. or intravenous (i.v.) administration of CEA CAR T cells.
RESULTS
Intraperitoneally administered CAR T cells exhibited superior anti-tumor activity compared with systemic i.v. cell infusion in an animal model of PC. In addition, i.p. administration conferred a durable effect and protection against tumor recurrence and exerted strong anti-tumor activity in an animal model of PC with metastasis in i.p. or extraperitoneal organs. Moreover, compared with systemic delivery, i.p. transfer of CAR T cells provided increased anti-tumor activity in extraperitoneal tumors without PC. This phenomenon was further confirmed in an animal model of pancreatic carcinoma after i.p. administration of our newly constructed prostate stem cell antigen-directed CAR T cells.
CONCLUSIONS
Taken together, our data suggest that i.p. administration of CAR T cells may be a robust delivery route for effective treatment of cancer.
论文信息
- 作者
- Qian S、Chen J、Zhao Y、Zhu X、Dai D、Qin L、Hong J、Xu Y
- 第一作者单位
- Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain. Electronic address: siyuanqz@gmail.com.Spain
- 通讯作者单位
- Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China. Electronic address: cqian8634@gmail.com.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Cytotherapy2024 Feb
- 原文标识
- PubMed 37999667 · DOI 10.1016/j.jcyt.2023.10.007